• LAST PRICE
    0.6450
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.6000/ 2
  • Ask / Lots
    0.6500/ 22
  • Open / Previous Close
    0.6400 / 0.6450
  • Day Range
    Low 0.6001
    High 0.6500
  • 52 Week Range
    Low 0.5287
    High 1.3800
  • Volume
    34,059
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.628
TimeVolumeTLSA
09:32 ET12450.64
09:51 ET12000.65
09:53 ET2000.63
10:18 ET3000.645
10:29 ET4000.645
10:31 ET4000.645
10:45 ET2800.645
11:12 ET3450.6445
11:16 ET8840.6445
11:32 ET11880.6445
11:48 ET6000.6445
12:03 ET1000.6445
12:06 ET171230.645
01:29 ET26000.6401
02:12 ET33000.6226
02:50 ET26000.645
03:19 ET1000.645
03:30 ET3000.6449
03:37 ET2000.645
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTLSA
Tiziana Life Sciences Ltd
66.0M
-3.8x
---
United StatesBCEL
Atreca Inc
65.6M
-0.6x
---
United StatesRPHM
Reneo Pharmaceuticals Inc
66.5M
-1.4x
---
United StatesBCLI
Brainstorm Cell Therapeutics Inc
66.5M
-2.6x
---
United StatesANEB
Anebulo Pharmaceuticals Inc
65.4M
-7.6x
---
United StatesLTRN
Lantern Pharma Inc.
65.4M
-4.6x
---
As of 2023-02-01

Company Information

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company. The Company specializes in developing transformative therapies for neurodegenerative diseases and gastrointestinal diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Crohn's Disease and KRAS+ NSCLC. The Company’s lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Crohn's disease, Pro-MS and autoimmune diseases, and its Milciclib (TZLS-201), is an orally bioavailable, small molecule, spectrum inhibitor of cyclin-dependent kinases (CDKs) (a family of highly conserved enzymes that regulate the cell cycle and cell division) and Src family kinases, which involved in regulating cell growth and potential transformation of normal cells to cancer cells. The Company is also focused on Anti Interlukin-6 Receptor mAB (TZLS-501), which is a fully human mAb that binds to both membrane-bound and soluble forms of IL-6R.

Contact Information

Headquarters
3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
Phone
207-495-2379
Fax
---

Executives

Executive Chairman of the Board
Gabriele Cerrone
Chief Executive Officer, Chief Scientific Officer, Executive Director
Kunwar Shailubhai
Finance Director
Keeren Shah
Senior Director, CMC and Non - Clinical Development
Jules Jacob
Senior Director, Clinical operations
Vaseem Palejwala

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$66.0M
Revenue (TTM)
$0.00
Shares Outstanding
102.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.63
EPS
$-0.17
Book Value
$0.00
P/E Ratio
-3.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.